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Background: With the wide application of targeted drug therapies, the relevance of prognostic and predictive
markers in patient selection has become increasingly important. Bevacizumab is commonly used in combination
with chemotherapy in the treatment of metastatic colorectal cancer. However, there are currently no predictive or
prognostic biomarkers for bevacizumab. Several clinical studies have evaluated bevacizumab-induced hypertension
in patients with metastatic colorectal cancer. This meta-analysis was performed to better determine the association
of bevacizumab-induced hypertension with outcome in patients with metastatic colorectal cancer, and to assess
whether bevacizumab-induced hypertension can be used as a prognostic factor in these patients.
Methods: We performed a systematic review and meta-analysis on seven published studies to investigate the
relationship between hypertension and outcome of patients with metastatic colorectal cancer treated with
bevacizumab. Our primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival
(OS) and overall response rate (ORR). Hazard ratios (HRs) for PFS and OS were extracted from each trial, and the log
of the relative risk ratio (RR) was estimated for ORR.
Results: The occurrence of bevacizumab-induced hypertension in patients was highly associated with
improvements in PFS (HR = 0.57, 95% CI: 0.46–0.72; P <0.001), OS (HR = 0.50; 95% CI: 0.37–0.68; P <0.001), and
ORR (RR = 1.57, 95% CI: 1.07–2.30, P <0.05), as compared to patients without hypertension.
Conclusions: Bevacizumab-induced hypertension may represent a prognostic factor in patients with metastatic
colorectal cancer.
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Colorectal cancer (CRC) is the fourth most common ma-
lignancy, and the second most frequent cause of cancer-
related death in the United States, given that as many as
20–25% of patients have already developed metastases at
initial diagnosis [1]. Vascular endothelial growth factor
(VEGF) is the major factor involved in tumor angiogenesis
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reproduction in any medium, provided the orpermeability, and stimulates the growth of blood vessels
supplying the tumor. Poor prognosis and an increased re-
lapse rate are often correlated with angiogenesis and in-
creased blood vessel density in the primary tumor. Thus,
anti-angiogenesis is a major topic of current research.
The VEGF signaling pathway is a target for cancer
therapy. A recombinant humanized monoclonal antibody
against VEGF, bevacizumab, has been developed to treat
metastatic CRC (mCRC), breast cancer, non-squamous
non-small cell lung cancer, renal cell carcinoma, ovarian
cancer, glioblastoma, and metastatic melanoma [3-11].
Treatment with bevacizumab, however, is associated
with various adverse reactions such as gastrointestinal. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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arterial thrombotic events, infection, proteinuria, and
hypertension. Nevertheless, the benefits of bevacizumab
treatment may still outweigh potential adverse events [12].
Furthermore, bevacizumab has been demonstrated to be
relatively safe in association with either irinotecan [13] or
oxaliplatin-containing chemotherapy regimens [14], while
its specific toxicity profile appears manageable by applying
appropriate clinical selection criteria [15].
As mentioned above, arterial hypertension is a com-
mon side effect of bevacizumab treatment usually easily
managed by standard anti-hypertensive therapy. Interest-
ingly, many clinical trials have found that patients with
mCRC treated with bevacizumab who developed hyper-
tension had a better prognosis than those without hyper-
tension [16-22]. These results were obtained through
retrospective analysis of a relatively small dataset, but
the findings are statistically significant and supported by
other studies [6]. Throughout the course of treatment
for mCRC, hypertension severity can be evaluated ob-
jectively and thus may be useful when making an early
decision on whether to alter the course of disease treat-
ment. The potential advantages of such a predictor in-
clude the ability to estimate the efficacy and activity of
anti-VEGF agents in patients with mCRC.
Thus, the purpose of this study was to perform a sys-
tematic review and conduct a meta-analysis to determine
if the occurrence of hypertension is a prognostic factor




The study was performed using a pre-specified search
strategy with a strict eligibility criteria. We did an exten-
sive search of PubMed to retrieve relevant literature that
reported the predictive value of hypertension regarding
response and/or progression and/or survival in mCRC
patients treated with bevacizumab. The search end date
was January 2013, with no specified start date. Search
term combinations were “bevacizumab”, “avastin”, and
“hypertension” in all fields. There were no limits for lan-
guage, methodological characteristics, or year of publica-
tion. All reference lists from the relevant articles and
reviews were also examined for additional eligible stud-
ies. This study is approved by the Ethic Commity of
Cancer Center of Union Hospital. And written informed
consent was obtained from the patient for the publica-
tion of this report and any accompanying images.
Selection of studies
Two reviewers (JC, HM) independently carried out a lit-
erature search and examined the relevant studies for fur-
ther assessment. The reference lists of all traced articleswere examined manually. Citations selected from this
initial search were subsequently screened for eligibility
using the following criteria: i) patients with mCRC; ii)
combined chemotherapy with bevacizumab, irrespective
of chemotherapy used; iii) studies involving the use of
other targeted agents were excluded to avoid bias related
to drug interactions; iv) curative effect comparison be-
tween bevacizumab-induced hypertension arm with no
hypertension arm; v) data available for analysis including
the incidence of hypertension and sample size.
Primary and secondary outcomes
The primary outcome was progression-free survival (PFS),
defined as the time between randomization and any pro-
gression or death from any cause, in relation to the severity
of hypertension in patients treated with bevacizumab. Sec-
ondary endpoints were overall survival (OS), the time be-
tween randomization and any death, and overall response
rate (ORR), the sum of partial and complete response rates
according to the Response Evaluation Criteria in Solid Tu-
mors [23] with hypertension occurrence as a predictor.
Hypertension was graded according to the National Cancer
Institute Common Terminology Criteria [24] for Adverse
Events (version 3.0, 2003). Grade 1 toxicity is defined as an
asymptomatic, transient increase (<24 h) greater than
20 mmHg diastolic or to greater than 150/100 mmHg.
Grade 2 is recurrent or persistent (>24 h) or a symptomatic
increase greater than 20 mmHg diastolic or to greater than
150/100 mmHg. Grade 3 is hypertension requiring ther-
apy or more intensive therapy than previously provided.
Grade 4 is a hypertensive crisis. Outcomes or responses
were evaluated by either a comparison between no-
hypertension (G0) and all grades of hypertension (G1–
4), or a comparison between low-grade hypertension
(G0–1) and high-grade hypertension (G2–4), depending
on the data available.
Data extraction
Two reviewers (JC, HM) retrieved data independently
and reached a consensus on all examined items. The fol-
lowing information was retrieved: first author, year of
publication, number of patients, number of patients eli-
gible for response, and median OS, PFS, ORR, and haz-
ard ratio (HR). For trials included in this meta-analysis,
if the log HR and its variance were not explicitly pre-
sented, the methods reported by Parmar et al. [25] were
used to extract estimates of these statistics. In the case
of any disagreement between the two reviewers, a third
reviewer (DCZ) would review the data, and the results
were attained by consensus. We contacted the authors
of trials for the missing data when necessary. Data of
study characteristics (concurrent treatment, number of
patients, bevacizumab dose, and publication time) and
clinical endpoints (PFS, OS, ORR) were then retrieved.
Table 1 Characteristics of the seven selected studies




Median PFS (m) Median OS (m) ORR (%)
HTN vs. No HTN HTN vs. No HTN HTN vs. No HTN
Scartozzi M/2009 [20] First-line 5 mg/kg/2w 39 14.5 vs. 3.1 NA vs. 15.1 75% vs. 32%
Rebekah/2009 [21] First-line NA 52 NA vs. NA NA vs. NA NA vs. NA
De Stefano/2011 [19] First-line 5 mg/kg/2w or
7.5 mg/kg/3w
74 15.1 vs. 8.3 35.5 vs. 26.7 84.6% vs. 42.6%
Osterlund P/2011 [17] First- or second-line 5 mg/kg/2w 101 10.5 vs. 5.3 25.8 vs. 11.7 52.6% vs. 45.5%
Horinouchi Y/2011 [18] First-line NA 36 16.25 vs. 10 NA vs. NA 60% vs. 23.1%
Dewdney A/2011 [22] First-line 7.5 mg/kg/3w 45 NA vs. NA NA vs. NA 71% vs. 78%
Tahover E/2013 [16] First- or second-line 2. 5 mg/kg/w 181 29.9 vs. 17.2 NA vs. 36.8 NA vs. NA





385 studies were excluded, 
because they were not related to 
the study of colorectal cancer
N=135 records 
screened
N=8 full text 
articles assessed for 
eligibility
127 articles were excluded, 
because they did not compare 
the presence of hypertension 
and effect of Bevacizumab.
N=7 studies included 
in quantitative 
synthesis
1 article was excluded, because 
it also related to other tumors
Figure 1 Study flow diagram.
Cai et al. World Journal of Surgical Oncology 2013, 11:306 Page 3 of 8
http://www.wjso.com/content/11/1/306
Overall  (I-squared = 0.0%, p = 0.963)
Osterlund P (2011)
Horinouchi Y (2011)
De Stefano A (2011)


























Figure 2 Forest plot for meta-analysis of hypertension occurrence and progression-free survival.
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We calculated relative risk ratios (RRs) and confidence
interval (CI) for ORR relating to hypertension severity in
patients with bevacizumab-induced hypertension versus
controls in the same trial. If the study reported HRs for
survival in patients with G0 vs. G1 or higher-grade hyper-
tension, then the comparison was made for the higher
grade of hypertension (for example G0 vs. G2 or G3 [or
G3–4]). Otherwise, if no other subgroups were reported,
the comparison was performed for G0 vs. G1–4 hyperten-
sion. HRs were extracted from each trial for PFS and OS,
and the log of relative RR was estimated for ORR, and
95% CIs were derived. The HR of each study was eitherOverall  (I-squared = 21.9%, p = 0.275)
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Figure 3 Forest plot for meta-analysis of hypertension occurrence andirectly collected from the original article, or calculated as
suggested by Parmar [25] and Tierney [26]. The number
of events (ORRs) was extracted from each study or calcu-
lated from the percentages provided.
A meta-analysis of both RRs and HRs was performed,
and both fixed-effect and random-effect models were
considered depending on the heterogeneity of the in-
cluded studies. Statistical heterogeneity among trials in-
cluded in the meta-analysis was assessed by using the
Cochran Q statistic, and inconsistency was quantified
with the I2 statistic that estimates the percentage of total
variation across studies due to heterogeneity rather than
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Figure 4 Forest plot for meta-analysis of hypertension occurrence and risk ratio.
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the fixed-effects model using the inverse variance method.
Otherwise, the pooled estimate was calculated based on
the random-effects model using the DerSimonian and
Laird method [28].
Publication bias was evaluated using funnel plots for
RR (plots of study results against precision), and with
the Begg’s [29] and Egger’s [30] tests. Additionally, sensi-
tivity analyses were performed to assess the influence of
each study on overall estimate for RR by sequential re-
moval of individual studies. A HR of less than one and a
RR value of more than one meant a benefit for patients
with bevacizumab-induced hypertension. A two-tailedFigure 5 Funnel plot for progression-free survival meta-analysis.P value <0.05 was considered statistically significant. All
statistical analyses were performed using STATA version
11.0 software (STATA, College Station, TX, USA).
Results
There were 520 publications retrieved from the PubMed
search. Among them, seven met the inclusion criteria for
this review. The study flow diagram is shown in Figure 1.
The main characteristics of the included articles (author/
year, reference, line of treatment, bevacizumab dose, num-
ber of patients, PFS, OS, ORR) are presented in Table 1.
Patients were enrolled according to pre-specified eligibility
criteria for each trial. Data regarding the predictive role of
Figure 6 Funnel plot for overall survival meta-analysis.
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Secondary outcome data, i.e., OS and ORR, were available
for five studies, respectively.
Efficacy
Median PFS
The occurrence of hypertension induced by bevacizu-
mab resulted in a statistically significant improvement in
PFS compared with no hypertension (HR = 0.57; 95% CI:Figure 7 Funnel plot for overall response rate meta-analysis.0.46–0.72, P <0.001; heterogeneity χ2 = 1.45, P for het-
erogeneity = 0.963; I2 = 0.0%) (Figure 2). There was no
heterogeneity between trials.
Median OS
Among the seven trials selected, five [16,17,19,21,22] in-
cluded relevant data. The pooled analysis showed that
the occurrence of hypertension induced by bevacizumab
also resulted in a statistically significant improvement in
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0.37–0.68, P <0.001; heterogeneity χ2 = 5.12, P for het-
erogeneity = 0.275; I2 = 21.9%) (Figure 3). Once again,
there was no heterogeneity between trials.ORR
Two studies [16,21] did not access this outcome, and
were thus excluded from the analysis. The remaining
five studies [17-20,22] contained pertinent data. Analysis
indicated hypertension induced by bevacizumab was as-
sociated with an increase in ORR (RR = 1.57, 95% CI:
1.07–2.30, P <0.05) (Figure 4). Because heterogeneity
was significant between trials (I2 = 63.7%, P = 0.026), a
combined effects model was used. Funnel plots and the
Egger’s test were used to assess publication bias. As
reflected in Figures 5, 6, and 7, the shape of the funnel
plots appeared symmetrical.Discussion
Bevacizumab is widely used as a standard treatment for
mCRC; the combined treatment of chemotherapy and
bevacizumab has significantly increased the PFS and OS
in patients with mCRC. Arterial hypertension is the most
common side effect of bevacizumab plus chemotherapy
treatment, with an overall incidence of 22–32%, and grade
3/4 events in 11–16% of patients [31,32]. While the
hypertension-causing mechanism of bevacizumab is un-
clear, it is fortunate that bevacizumab-induced hyperten-
sion rarely induces severe or life-threatening outcomes.
To date, no specific predictive or prognostic biomarkers
for bevacizumab treatment have been identified. Some
studies have suggested that bevacizumab-induced hyper-
tension could represent a valuable prognostic factor of
clinical outcome in advanced-stage CRC patients [16-21].
Thus, it would be interesting to see if hypertension could
be a predictive factor in patients with mCRC.
To our knowledge, this is the first meta-analysis that
systematically evaluates the correlation of hypertension
with survival and response in mCRC patients treated
with bevacizumab. Our results indeed demonstrate that
bevacizumab-induced hypertension in mCRC patients is
significantly associated with PFS and OS. Also, our meta-
analysis indicate that the occurrence of hypertension in-
duced by bevacizumab is associated with a statistically
significant improvement in ORR, in line with previous
studies [19,20].
An outstanding benefit of our study is that patients
who are more suitable to bevacizumab treatment could
eventually be screened and selected for targeted therapy.
Furthermore, it would be of extreme benefit to the fight
against cancer if these results were comparable with the
outcomes of anti-EGFR monoclonal antibody and KRAS
status in CRC [33,34].Conclusions
Caution is certainly needed before we may conclude that
bevacizumab-induced hypertension is a reliable bio/clin-
ical marker for early screening and diagnosis of patients
with mCRC due to the limitation on available data and
the relatively small sample size of our study. However, our
results should undoubtedly lead to larger sample size,
multiple-center clinical studies as well as analyses to
further elucidate the correlation between bevacizumab-
induced hypertension and mCRC. Thus, feasible and
efficient methods to diagnose and treat patients with
mCRC at earliest possible stages could be developed.
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